TOWARDS A CONSTRUCTIVE DEBATE AND COLLABORATIVE EFFORTS TO RESOLVE CURRENT CHALLENGES IN THE DELIVERY OF NOVEL CELL BASED THERAPEUTIC STRATEGIES.

Soon after the Cell Transplant Society (CTS) was formed in 1991, with E. Donnall Thomas, Thomas E. Starzl and Paul E. Lacy serving as Honorary Presidents, we were worned at that time of CTS first congress (1992) about the potential risk of overregulation by FDA of the emerging field of cellular therapies.